Exclusive Worldwide Agreement Will Allow Valensa to Develop Next-Generation Omega-3 Condition-Specific Formulations
ORLANDO, Fla., Dec. 8, 2009 — Valensa International (Eustis, FL USA) announced today that it has reached an exclusive agreement with Aker BioMarine ASA (Oslo, Norway) to use Aker BioMarine's Superba(R) krill oil in condition-specific dietary supplement formulas targeting joint health and eye health. Valensa plans on using the highly bio-available Omega-3 phospholipids of Aker BioMarine's Superba(TM) krill oil, in conjunction with several of its own proprietary ingredients such as Zanthin(R) Natural Astaxanthin, extending its current platform of patented and patent-pending formulations. Valensa has developed and filed provisional patents for a revolutionary range of joint and eye healthcare dietary supplement and medical food formulations featuring Superba(TM) krill oil and additional scientifically sound condition-specific ingredients. Valensa also announced that it had terminated a similar agreement with Neptune Technologies & Bioressources Inc. on November 9, 2009.
According to Dr. Rudi E. Moerck, President & CEO of Valensa, the relationship with Aker BioMarine represents the coming together of two companies with similar views of the marketplace. "We're excited to be working with Aker BioMarine because of their product quality, their vision, their energy and their commitment to driving the use of Superba(TM) krill oil to improve human health. They have an excellent understanding of the market potential for this ingredient, world-class supply ability and are excited about Valensa's plans to bring Superba(TM) krill oil to market in condition-specific formulas," he said. "Working with Aker BioMarine executives has been a real pleasure," he added.
On October 6, 2009, Valensa announced that it had reached a similar exclusive agreement involving krill oil with Neptune Technologies & Bioressources Inc. That agreement was terminated by Valensa on November 9, 2009 due to irreconcilable differences between the two companies over the ability of Neptune to deliver the product it had promised and differing interpretations of agreement language. Discussions with Aker BioMarine began after the termination of the agreement with Neptune.
For further information, contact:
Dr. Rudi E. Moerck, President
Voice: 210-632-0695
Fax: 352-483-2095
According to Moerck, the upside potential for Superba(TM) krill-based formulations from Valensa is substantial. "Joint and eye health are major concerns for many people including the aging baby-boomer population who also want small dosage forms that are easy to use on a regular basis. The increased potency of formulas containing Superba(TM) krill allows formulators and marketers to substantially reduce the size of their softgels and dramatically reduce the overall 'pill burden' on people. Incorporating enriched krill into exciting new proprietary products for joint health and eye health allows Valensa the opportunity to address a range of market and consumer needs," he said.
# # #